Latest news and press releases about Janux Therapeutics, Inc. (JANX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors.
Price
| Price | $16.25 |
| Market Cap | $991M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.09 |
| EV / EBITDA | -11.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -10.79% |
| Return on Invested Capital | -15.11% |
| Return on Assets | -10.18% |
| Gross Margin | 68.91% |
| Operating Margin | -450.30% |
| Net Margin | -321.81% |
Related companies: ABCL · BHVN · CLDX · HRMY · IMNM · MAZE · NUVB
Explore sector: Healthcare · Biotechnology
More sections of JANX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks